ReviewCancers2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Clinical and economic research of bone modifiers as adjuvant therapy for early breast cancer: A systematic literature review.Breast (Edinburgh, Scotland) · 2025Pooled it
- The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials.Breast (Edinburgh, Scotland) · 2024Pooled it
- Association between NDRG1 protein expression and aggressive features of breast cancer: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- Optimizing axillary lymph node management in early-stage HR+/HER2- breast cancer: Practical strategies for enhanced detection rates.Breast (Edinburgh, Scotland) · 2026Article
- Tumor biology, treatment patterns, and recurrence in breast cancer patients aged 70-79 vs ≥ 80 years: a large-scale registry analysis.Archives of gynecology and obstetrics · 2026Article
- Advances in Immunotherapy for Breast Cancer.Oncology (Williston Park, N.Y.) · 2026Review
- Development of a Consensus-Based Risk Stratification Algorithm for HR+/HER2- Early Breast Cancer to Guide Adjuvant CDK4/6i Therapy: Outcomes from a Multidisciplinary Workshop in India.Breast cancer (Dove Medical Press) · 2026Article
- Microbial assisted zinc biofortification of wheat germplasm for the amelioration of zinc malnutrition.Scientific reports · 2025Article
- Risk factors of sentinel lymph node metastasis in early-stage invasive breast cancer.Scientific reports · 2025Article
- The level of estrogen receptor (ER) expression and the length of adjuvant hormonal therapy in ER positive breast cancer.Gland surgery · 2025Article
- Review
- Part I: consensus statements and expert recommendations forFrontiers in oncology · 2025Review
- PLCH1 overexpression promotes breast cancer progression and predicts poor prognosis through the ERK1/2-EGR1 axis.Frontiers in oncology · 2025Article
- Patient outcomes and clinician perspectives following one year ofTranslational breast cancer research : a journal focusing on translational research in breast cancer · 2025Article
- Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management.Frontiers in oncology · 2025Review
- Review
- Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials.Breast (Edinburgh, Scotland) · 2024Review
- Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.Cancers · 2024Review
- Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.Geburtshilfe und Frauenheilkunde · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 18 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2-negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/HER2-negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2-negative early breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.